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ABSTRACT 
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic 
disease, both in the venous and arterial circulations, due to excessive inflammation, platelet 
activation, endothelial dysfunction, and stasis. In addition, many patients receiving 
antithrombotic therapy for thrombotic disease may develop COVID-19, which can have 
implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, 
during a time with much focus on COVID-19, it is critical to consider how to optimize the 
available technology to care for patients without COVID-19 who have thrombotic disease. 
Herein, we review the current understanding of the pathogenesis, epidemiology, management 
and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of 
those with preexisting thrombotic disease who develop COVID-19, or those who need 
prevention or care for their thrombotic disease during the COVID-19 pandemic. 
 
KEYWORDS: Coronavirus disease 2019, SARS-CoV-2, thrombosis, antithrombotic therapy, 
anticoagulant, antiplatelet 
 
ABBREVIATIONS 
ACS = acute coronary syndromes 
COVID-19 = coronavirus disease 2019 
DAPT = dual antiplatelet therapy 
DIC = disseminated intravascular coagulation 
DOAC = direct oral anticoagulant 
DVT = deep vein thrombosis 
ECMO = extracorporeal membrane oxygenation 
LMWH = low-molecular-weight heparin 
PE = pulmonary embolism 
PERTs = pulmonary embolism response teams 
SARS-CoV2 = severe acute respiratory syndrome coronavirus 2 
STEMI = ST-segment elevation myocardial infarction 
UFH = unfractionated heparin 
VEGF = vascular endothelial growth factor 
VKA = vitamin-K antagonist 
VTE = venous thromboembolism 
  
7 
Introduction 
The coronavirus disease of 2019 (COVID-19) is a viral illness caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV2), now deemed a pandemic by the World 
Health Organization (1-3). COVID-19 has a number of important cardiovascular implications (4-
6). Patients with prior cardiovascular disease are at higher risk for adverse events from COVID-
19. Individuals without a history of cardiovascular disease are at risk for incident cardiovascular 
complications (5). 
There are several ways in which the COVID-19 pandemic may affect the prevention and 
management of thrombotic and thromboembolic disease (hereafter collectively referred to as 
thrombotic disease for brevity). First, the direct effects of COVID-19 or the indirect effects of 
infection, such as through severe illness and hypoxia, may predispose patients to thrombotic 
events. Preliminary reports suggest that hemostatic abnormalities, including disseminated 
intravascular coagulation (DIC), occur in patients affected by COVID-19 (7,8). Additionally, the 
severe inflammatory response, critical illness, and underlying traditional risk factors may all 
predispose to thrombotic events, similar to prior virulent zoonotic coronavirus outbreaks (Table 
1) (9,10). Second, investigational therapies for treating COVID-19 may have adverse drug-drug 
interactions with antiplatelet agents and anticoagulants. Third, the pandemic, because of resource 
allocations or social distancing recommendations, may adversely affect the care of patients 
without COVID-19 but who present with thrombotic events. For example, (mis)perception that 
antithrombotic agents confer increased risk for contracting COVID-19, may lead to untoward 
interruption of anticoagulation by some patients. 
The current manuscript, authored by an international collaborative of clinicians and 
investigators, summarizes the pathogenesis, epidemiology, treatment, and available outcome data 
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related to thrombotic disease in patients with COVID-19, as well as management of thrombotic 
events in patients without COVID-19 during this pandemic. Although the focus is on the 
prevention and management of venous thromboembolism (VTE) and antithrombotic therapy for 
acute coronary syndromes (ACS), many of the recommendations are relevant to other conditions 
requiring antithrombotic therapy. We provide clinical guidance, when feasible, and also identify 
areas that require urgent attention for future research. 
Methodological Considerations 
Every effort was made to provide a comprehensive assessment of the published evidence 
(MEDLINE with PubMed interface, date of last search: April 12, 2020). To accommodate the 
rapidly-evolving nature of information and concern for the delay between completion of studies 
and their publication, we also reviewed manuscripts on two pre-print servers 
(https://www.medrxiv.org/ and https://www.ssrn.com/index.cfm/en/coronavirus/, date of last 
search April 12, 2020). We acknowledge that the manuscripts from the latter two sources are not 
peer-reviewed.  
There is international variability in preventive measures and testing strategies by local 
authorities, diagnostic tests availability, access to care and treatment strategies, as well as 
variability in outcome reporting for COVID-19. These issues influence the reported diagnosed 
cases, casualties, and in turn case-fatality rates. Moreover, to date, we lack large prospective 
cohorts. The existing evidence, including data on thrombotic complications, is derived primarily 
from small and retrospective analyses (Figure 1). 
The current document represents an effort to provide general guidance for patient-care 
related to thrombosis and antithrombotic therapy. Given the limitations of the evidence base, the 
steering committee (BB, MVM, JIW, SK, SZG, AT, MM, HMK, GYHL) chose several 
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questions that seemed more challenging but relevant to patient care (11). These questions were 
sent to the entire group of authors twice. The Delphi method was implemented to provide 
consensus-based guidance. The questions included considerations for prophylactic or therapeutic 
anticoagulant regimens among various subgroups of patients with COVID-19, and 
antithrombotic therapy in the setting of suspected or confirmed DIC. 
Pathogenesis and Transmission 
SARS-CoV2 is a single-strand RNA coronavirus, which enters human cells mainly by 
binding the angiotensin converting enzyme 2 (ACE2) (12), which is highly expressed in lung 
alveolar cells, cardiac myocytes, the vascular endothelium, and other cells (1,13). SARS-CoV2 is 
transmitted primarily after viral particles are inhaled and enter the respiratory tract (1). In 
addition, the virus can survive for 24-72 hours on surfaces, depending on the type of surface, 
which enables fomite transmission (14). 
Initial symptoms of COVID-19 overlap with other viral syndromes, and include fever, 
fatigue, headache, cough, shortness of breath, diarrhea, headaches, and myalgias (15-17). As 
with other virulent zoonotic coronavirus infections such as severe acute respiratory syndrome 
(SARS) and Middle Eastern respiratory syndrome (MERS-CoV), COVID-19 has the potential to 
result in severe illness including systemic inflammatory response syndrome, acute respiratory 
disease syndrome (ARDS), multi-organ involvement, and shock (18). Although older age and 
comorbidities such as cardiovascular disease confer a higher risk for severe disease, young and 
otherwise healthy patients are also at risk for complications (19). 
 Common laboratory abnormalities found in patients with COVID-19 include 
lymphopenia (15) and elevation in lactate dehydrogenase and inflammatory markers such as, C-
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reactive protein, D-dimer, ferritin and interleukin-6 (IL-6) (20). IL-6 levels may correlate with 
disease severity, and a procoagulant profile (21). 
COVID-19 and Hemostasis Parameters 
The most consistent hemostatic abnormalities with COVID-19  include mild 
thrombocytopenia (22) and increased D-dimer levels (23), which are associated with a higher 
risk of requiring mechanical ventilation, intensive care unit [ICU] admission, or death. Data 
related to other tests are less certain and often contradictory (24,25). Disease severity is variably 
associated with prolongation of the prothrombin time (PT) and international normalized ratio 
(INR) (1,20,26), and thrombin time (TT) (27), and variably by a trend toward shortened activated 
partial thromboplastin time (aPTT) (1,16,19,28). Recently, Tang et al. (7) assessed 183 patients 
with COVID-19, 21 of whom (11.5%) died. Among the notable differences between patients 
who died and those who survived were increased levels of D-dimer and fibrin degradation 
products ([FDPs], ~3.5- and ~1.9-fold increase, respectively) and PT prolongation (by 14%, 
P<0.001). Further, 71% of COVID-19 patients who died fulfilled the International Society on 
Thrombosis and Haemostasis (ISTH) criteria (29) for DIC, compared with only 0.6% among 
survivors. Collectively, these hemostatic changes indicate some forms of coagulopathy that may 
predispose to thrombotic events (Central Illustration), although the cause is uncertain.  
Nevertheless, it is yet unknown whether these hemostatic changes are a specific effect of 
SARS-CoV-2 or are a consequence of cytokine storm that precipitates the onset of systemic 
inflammatory response syndrome (SIRS), as observed in other viral disease (30-33). Another 
consideration which has not yet been investigated is that the hemostatic changes seen with 
COVID-19 infection are related to liver dysfunction (34). A recent study reported 3 cases with 
severe COVID-19 and cerebral infarction, one associated with bilateral limb ischemia, in the 
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setting of elevated antiphospholipid antibodies. Whether antiphospholipid antibodies play a 
major role in pathophysiology of thrombosis associated with COVID-19 requires further 
investigation (35). 
COVID-19, markers of myocardial injury, and thrombotic disease. Elevated troponin 
levels are associated with poor outcomes in several studies of COVID-19 (36). However, the 
differential diagnosis for elevated troponin in COVID-19 is broad (37) and includes non-specific 
myocardial injury, impaired renal function (leading to troponin accumulation), myocarditis, 
pulmonary embolism (PE), and Type I and II myocardial infarction (MI) (38,39). Similarly, 
elevation of natriuretic peptides is non-specific (38), and consideration for thrombotic events 
(e.g., PE) should only be raised in the appropriate clinical context.  
COVID-19 Investigational Therapies and Considerations for Thrombotic Disease 
Several investigational agents are being tested in the management of COVID-19, 
especially for patients who develop severe disease. Some of these drugs have clinically important 
interactions with antiplatelet or anticoagulant agents (Tables 4 and 5).  
Further, a few of these investigational agents have been associated with excess risk (or, in 
other cases, reduced risk) for thrombotic events, or for thrombocytopenia in prior studies of non-
COVID-19 populations. For example, bevacizumab, a monoclonal antibody that binds to 
vascular endothelial growth factor (VEGF), and is under investigational use for COVID-19, is 
associated with increased risk for adverse cardiovascular events, including MI, cerebrovascular 
accidents, and VTE (40,41). Alternatively, fingolimod, an immunomodulating agent being tried 
for COVID-19, may reduce reperfusion injury and improve outcomes in patients suffering from 
acute ischemic stroke (42). Hydroxychorloquine, recently receiving Emergency Use 
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Authorization from the U.S. Food and Drug Administration for treatment of COVID-19, may 
potentially exert antithrombotic properties, especially against anti-phospholipid antibodies (43). 
COVID-19 investigational therapies and antiplatelet agents.  
Scientists are studying a number of agents for COVID-19 treatment that may have 
interactions with oral antiplatelet agents. Table 3 presents potential drug interactions between 
investigational drugs for COVID-19 and commonly administered oral antiplatelet agents. 
Lopinavir/ritonavir is a protease inhibitor and inhibits CYP3A4 metabolism. Although the active 
metabolite for clopidogrel is mostly formed by CYP2C19, inhibition of CYP3A4 may also lead 
to reduction in effective dosage of clopidogrel. In contrast, inhibition of CYP3A4 may increase 
effects of ticagrelor. Therefore, the concomitant use of these agents along with 
lopinavir/ritonavir should be cautioned. Although limited clinical data exist, use of P2Y12 platelet 
function testing to guide the use of clopidogrel or ticagrelor in this setting might be considered. 
An alternative, in the absence of contraindications, is to use prasugrel, which is not prone to 
these interactions (44-47). Remdesivir, a nucleotide-analog inhibitor of RNA-dependent RNA 
polymerase, reportedly an inducer of CYP3A4; however, dose adjustments for oral antiplatelet 
agents are currently not recommended. Of note, there are no major drug-drug interactions 
between investigational COVID-19 therapies and parenteral antiplatelet agents such as cangrelor 
and glycoprotein IIb/IIIa inhibitors. 
COVID-19 investigational therapies and anticoagulants.  
Table 4 summarizes interactions between investigational drugs for COVID-19 and 
commonly administered oral anticoagulants. Lopinavir/ritonavir has the potential to also affect 
choice and dosage of a number of anticoagulants. For example, vitamin K antagonists, apixaban, 
and betrixaban may all require dose adjustment, while edoxaban and rivaroxaban should not be 
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co-administered with lopinavir/ritonavir. Tocilizumab, an IL-6 inhibitor, increases expression of 
CYP3A4; however, no anticoagulant dose adjustments are currently recommended with 
concomitant use of tocilizumab at this time. There are no major drug-drug interactions between 
investigational COVID-19 therapies and parenteral anticoagulants. Although the focus of the 
current manuscript is primarily related to VTE and ACS, the guidance provided for 
antithrombotic considerations is broadly relevant across other clinical indications. 
COVID-19 and VTE 
Risk stratification and in-hospital prophylaxis.  
Hospitalized patients with acute medical illness, including infections such as pneumonia, 
are at increased risk of VTE (48,49). Prophylactic anticoagulation reduces the risk of VTE in 
acutely ill hospitalized medical patients (50-52), and appropriate use of VTE prophylaxis is 
covered in clinical practice guidelines (49,53,54). Multiple risk stratification tools are available 
for VTE risk assessment in this setting (e.g. the Caprini, IMPROVE, and Padua models) (55-60). 
The choice of specific risk assessment model may vary across health system. However, 
similar to other acutely ill medical patients, VTE risk stratification for hospitalized patients with 
COVID-19 should be undertaken. A recent study from China, using the Padua model, reported 
that 40% of hospitalized patients with COVID-19 were at high risk of VTE. The study did not 
provide data about the use of VTE prophylaxis, or the incident VTE events (61). Hospitalized 
patients with COVID-19 who have respiratory failure or co-morbidities (e.g., active cancer, or 
heart failure) (62), patients who are bedridden, and those requiring intensive care should receive 
pharmacological VTE prophylaxis, unless there are contraindications. The choice of agents and 
dosing should be based on available guideline recommendations (53,54,63). The World Health 
Organization interim guidance statement recommends prophylactic daily low-molecular weight 
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heparins (LMWHs), or twice daily subcutaneous unfractionated heparin (UFH) (64). If 
pharmacological prophylaxis is contraindicated, mechanical VTE prophylaxis (intermittent 
pneumatic compression) should be considered in immobilized patients (64,65). Missed doses of 
pharmacologic VTE prophylaxis are common and are likely associated with worse outcomes 
(66). Therefore, every effort should be made to ensure that patients receive all scheduled doses 
of pharmacologic VTE prophylaxis. In this regard, once daily dosing regimen of LMWHs may 
be advantageous over UFH to reduce personal protective equipment (PPE) use and exposure of 
healthcare workers. 
Consideration for risk of VTE in pregnant patients with COVID-19 deserves further 
attention. The risk of VTE is increased during pregnancy and the postpartum period (67,68). 
Although limited data are available, pregnant women admitted to hospital with COVID-19 
infection are likely to be at an increased risk of VTE. It is reasonable to assess the risk of VTE 
and to consider pharmacological thromboprophylaxis, especially if they have other VTE risk 
factors. Weight-adjusted prophylactic dosing of anticoagulation is an interesting topic that 
requires additional investigation (69). 
Extended (post-discharge) VTE prophylaxis.  
 After hospital discharge from acute medical illness, extended prophylaxis with LMWH 
(70) or direct oral anticoagulants (DOACs) (71-74) can reduce the risk of VTE, at the cost of 
increase in bleeding events, including major bleeding (75,76). While no data specific to COVID-
19 exist, it is reasonable to employ individualized risk stratification for thrombotic and 
hemorrhagic risk, followed by consideration of extended prophylaxis (for up to 45 days) for 
patients with elevated risk of VTE (e.g., reduced mobility, co-morbidities such as active cancer, 
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and [according to some authors in the writing group], elevated D-dimer >2 times the upper 
normal limit) who have low risk of bleeding (74,77,78). 
The role of thromboprophylaxis for quarantined patients with mild COVID-19 but 
significant co-morbidities, or for patients without COVID-19 who are less active because of 
quarantine is uncertain. These patients should be advised to stay active at home. In the absence 
of high-quality data, pharmacological prophylaxis should be reserved for those at highest risk 
patients, including those with limited mobility and history of prior VTE or active malignancy. 
Diagnosis of VTE in patients with COVID-19.  
As described above, elevated D-dimer levels, is a common finding in patients with 
COVID-19 (23), and does not currently warrant routine investigation for acute VTE in absence 
of clinical manifestations or other supporting information. However, the index of suspicion for 
VTE should be high in the case typical DVT symptoms, hypoxemia disproportionate to known 
respiratory pathologies, or acute unexplained right ventricular dysfunction.  
A diagnostic challenge arises among patients with COVID-19, as imaging studies used to 
diagnose DVT or PE may not be pursued given risk of transmitting infection to other patients or 
healthcare workers and potentially due to patient instability. Moreover, imaging studies may be 
challenging in the setting of patients with severe ARDS who require prone positioning. 
Investigation for PE is not feasible due to critical illness and prone position. Lower extremity 
ultrasound is also limited due to patient positioning. Deterioration of right ventricular function in 
this setting may be a critical finding, justifying the need for ways to diagnose and treat PE. 
However, it may be argued that the prognosis of patients with ARDS requiring prone position is 
so grave that investigation for underlying VTE may not alter the course. A potential option may 
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be to consider echocardiography to assess for signs of potentially worsening right ventricular 
dysfunction and in rare circumstances, clot in transit (79). 
Role for empiric therapeutic anticoagulation without a diagnosis of VTE.  
In view of the hemostatic derangements discussed above and observations from prior 
viral illnesses (80), some clinicians use intermediate-dose or full dose (therapeutic) parenteral 
anticoagulation (rather than prophylactic dosing) for routine care of patients with COVID-19 
(81), hypothesizing that it may confer benefit to prevent microvascular thrombosis. However, the 
existing data are very limited, primarily based on a subgroup analysis (N=97) from a single 
retrospective study with limited control for potential confounders (82). A single center study 
from China suggested that D-dimer levels >1,500ng/mL has a sensitivity of 85.0% and 
specificity of 88.5% for detecting VTE events. However, the study was limited by small sample 
size and lack of validation. At this moment, while practitioners use a variety of prophylactic, 
intermediate, or therapeutic doses of anticoagulants in patients, the optimal dosing in patients 
with severe COVID-19 remains unknown and warrants further prospective investigation. The 
majority of panel members consider prophylactic anticoagulation, although a minority consider 
intermediate-dose or therapeutic dose to be reasonable. 
Incident venous thromboembolism.  
Few published studies have commented on incident VTE in patients with COVID-19. In 
a retrospective study from China, among 81 patients with severe COVID-19 admitted to ICU, 20 
(25%) developed incident VTE. Of note, none of the patients had received VTE prophylaxis 
(85). In an preprint study of 25 patients with COVID-19 from Wuhan, who were suspected of 
having PE and underwent computed tomography angiography (CTA), 10 (40%) had evidence of 
acute PE on imaging (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548771); however, 
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the study did not provide information related to use of VTE prophylaxis or the reason for 
performing CTA. In a study of 184 patients with severe COVID-19 from 3 academic medical 
centers in the Netherlands, the authors reported that 31% (95%CI 20-41) of patients developed 
incident VTE. All patients received pharmacological prophylaxis, although under-dosing was 
observed in 2 of the 3 participating centers (81). These findings require validation in additional 
studies. 
It is possible but unknown that VTE remains underdiagnosed in patients with severe 
COVID-19. This is important, as ARDS in patients with COVID-19 is, itself, a potential etiology 
for hypoxic pulmonary vasoconstriction, pulmonary hypertension and right ventricular failure. 
Further insult from PE may be unrecoverable. 
Medical therapy for VTE.  
Therapeutic anticoagulation is the mainstay of VTE treatment (49,86,87). Selection of an 
agent requires consideration of comorbidities such as renal or hepatic dysfunction, 
thrombocytopenia and gastrointestinal tract function, and the agent will likely change across the 
hospital course to the time of discharge. In many ill inpatients with VTE, parenteral 
anticoagulation (e.g. UFH) is preferred as it may be temporarily withheld and has no known 
drug-drug interactions with investigational COVID-19 therapies. Concerns with UFH, however, 
include the time to achieve therapeutic aPTT, and increased healthcare worker exposure for 
frequent blood draws. Therefore, LMWHs may be preferred in patients unlikely to need 
procedures. The benefit of oral anticoagulation with DOACs include the lack of need for 
monitoring, facilitation of discharge planning, and outpatient management. The potential risk 
(especially in the setting or organ dysfunction) may include clinical deterioration and lack of 
timely availability of effective reversal agents at some centers. For patients who are ready for 
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discharge, DOACs or LMWH would be preferred to limit contact of patients with healthcare 
services required for INR monitoring for VKAs. 
COVID-19 and interventional therapies for VTE.  
Pulmonary embolism response teams (PERTs) allow for multidisciplinary care for 
patients intermediate and high-risk with VTE (49,88-90). During the COVID-19 pandemic, 
similar to other consultative services, PERTs should transition from in-person inpatient 
evaluation to e-consults using phone calls or telemedicine systems whenever feasible. It is 
important to note that, there are minimal available data demonstrating lower mortality from 
routine use of advanced VTE therapies (91,92). Therefore, the use of catheter-directed therapies 
during the current outbreak should be limited to the most critical situations. Indiscriminate use of 
inferior vena cava filters should be avoided (93). Recurrent PE despite optimal anticoagulation, 
or clinically-significant VTE in the setting of absolute contraindications to anticoagulation would 
be among the few scenarios in which placement of an inferior vena cava filter may be considered 
(11). Even after IVC filter placement, anticoagulation should be resumed as soon as feasible, and 
this is often done with gradually increasing doses and close observation for bleeding. With 
regard to reperfusion strategies for acute PE, current guideline recommendations should be 
followed. Intermediate-risk hemodynamically stable patients (intermediate-low risk, or 
intermediate-high risk PE according to ESC classification, sub-massive PE according to prior 
classifications) (49,87,91,94) should be managed initially with anticoagulation and close 
monitoring. In case of further deterioration, rescue systemic fibrinolysis should be considered, 
with catheter-directed options as an alternative. For patients with overt hemodynamic instability 
(high-risk PE according to the ESC classification, massive PE according to prior classifications) 
(49,87,91,94) systemic fibrinolysis is indicated, with catheter-based therapies reserved for 
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scenarios that are not suitable for systemic fibrinolysis. If infection control settings are equal, 
bedside initiation of extracorporeal membrane oxygenation (ECMO) is preferred in cases with 
known COVID-19 positivity or uncertain status, rather than support strategies requiring the use 
of a catheterization laboratory or an operating room (95). Figure 2 presents a potential algorithm 
for treatments based on risk due to VTE and COVID-19 severity. 
The vast majority of patients with symptomatic acute deep venous thrombosis (DVT), 
should be managed with anticoagulation, with home treatment whenever possible. The few that 
may require acute endovascular techniques (either local fibrinolysis or embolectomy) include 
those with phlegmasia, or truly refractory symptoms (96). 
COVID-19 and Acute Coronary Syndromes 
COVID-19 and incident ACS.  
Myocardial injury in COVID-19, as evidenced by elevated cardiac troponin levels or 
electrocardiographic and echocardiographic abnormalities, is associated with severe disease.7 
Furthermore, higher troponin levels are associated with severe COVID-19 (5,97). However, not 
all such events are due to thrombotic ACS. While anecdotal cases of patients with COVID-19 
presenting with ACS due to plaque-rupture have been described (type I MI), currently no such 
cases have been published. Such cases have been also previously described with influenza or 
other viral illnesses, and have been attributed to a combination of SIRS as well as localized 
vascular/plaque inflammation (10,98,99). 
COVID-19 and antithrombotic therapy for ACS.  
In presentations consistent with ACS due to plaque rupture (i.e. Type I MI) (39), dual 
antiplatelet therapy (DAPT) and full dose anticoagulation per American College of Cardiology 
(ACC)/American Heart Association (AHA) and the European Society of Cardiology (ESC) 
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guidelines should be administered unless there are contraindications (100-103). In patients with 
perceived elevated bleeding risk, regimens with less potent antiplatelet agents, such as with 
clopidogrel, should be considered given that hemorrhagic complications are not uncommon. 
Special attention should be also given to drug-drug interactions between antiplatelet agents or 
anticoagulants and COVID-19 investigational therapies. Parenteral antithrombotic agents, in 
general, do not have known major interactions with the COVID-19 investigational therapies 
(Tables 4, 5). 
COVID-19 and interventional therapies for ACS.  
The American College of Cardiology (ACC) and Society for Cardiovascular 
Angiography and Interventions (SCAI) recently provided guidance regarding catheterization 
laboratory procedures in the current climate (84,104). The recommendations note that it is 
reasonable to continue optimal medical therapy and defer non-urgent cardiac procedures, in 
order to preserve PPE, hospital resources including inpatient and ICU beds, and minimize 
exposure for patients and healthcare workers, alike.  
Prior to intervention, efforts should be made to distinguish non-specific myocardial 
injury, myocarditis, and true plaque rupture presentations (104). A low threshold to use 
transthoracic echocardiography to identify wall motion abnormalities should be considered prior 
to catheterization laboratory activation. Even in case of STEMI, in which primary percutaneous 
coronary intervention (PCI) reduces mortality and reinfarction, risk of COVID-19 transmission 
from patients to healthcare workers, or vice versa (asymptomatic vectors) must be considered. In 
light of this, individual centers in China and elsewhere have developed adjusted ACS protocols, 
which call for consideration of fibrinolytic therapy in selected patients with STEMI (105). 
Centers in which timely percutaneous coronary intervention is less feasible may be more likely 
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to adopt such a strategy. However, given that presentations of COVID-19 can mimic ACS (e.g. 
in the setting of myocarditis), fibrinolytic therapy must be used with caution. 
Critical Illness with SARS-CoV-2 and Management of Antithrombotic Agents 
The risk of VTE, which is increased in critically ill patients, is likely even higher in those 
with SARS-CoV-2 and critical illness. Aside from hemostatic derangements, immobility, an 
systemic inflammatory state, mechanical ventilation and central venous catheters contribute to 
VTE risk within the ICU (106-108), Nutritional deficiencies and liver dysfunction may also 
interfere with the production of coagulation factors (109). Alterations in pharmacokinetics in 
critically ill patients may necessitate anticoagulation dose adjustment (110), due to factors 
relating to absorption, metabolism, and renal (or hepatic) elimination of these drugs in the setting 
of potential organ dysfunction.  
Parenteral anticoagulation is recommended in most cases in which anticoagulant therapy 
is needed for known thrombotic disease. UFH can be used in the setting of anticipated 
procedures, or in patients with deteriorating renal function. If no urgent procedures are 
anticipated, LMWHs are a reasonable alternative (111). In patients requiring ECMO, 
anticoagulation is frequently required to maintain circuit patency, especially at lower flow 
settings. Rates of complications are unknown in patients with SARS-CoV-2, but rates of 
thrombosis and hemorrhage may be as high as 53% and 16%, respectively, in other populations 
with respiratory failure (112). The limited outcome data that are available for ECMO in patients 
with SARS-CoV-2 suggest poor outcomes, with 5 of 6 patients dying in one series and 3 out of 3 
in another (113,114). There are currently insufficient data to recommend anticoagulation targets 
for COVID-19 patients requiring ECMO (115). 
Additional considerations.  
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As previously mentioned, severe COVID-19 may predispose to DIC with such patients 
experiencing particularly poor outcomes (7). Supportive care and addressing the underlying 
hypoxia or co-infection are appropriate (29). There are insufficient data to recommend 
transfusion thresholds that differ from those recommended for other critically ill patients. If 
invasive procedures are planned, prophylactic transfusion of platelets, fresh frozen plasma, 
fibrinogen, and prothrombin complex concentrate may be considered (29). Lastly, patients 
requiring targeted temperature management may exhibit prolongations of both PT and aPTT 
without evidence of bleeding diathesis (116). Therefore, correction of coagulopathy in 
unselected patients without overt bleeding, is not currently recommended. 
DIC and Considerations for Antithrombotic Therapy  
Diagnosis and management.  
DIC is common in many patients with critical illness (117), including those with COVID-
19 (7,118). It is uncertain whether COVID-19 has unique characteristics to cause direct 
activation of coagulation. The diagnosis of DIC is best established using the ISTH DIC score 
calculator (29). Regular laboratory monitoring of platelet count, PT, D-dimer, and fibrinogen in 
patients with COVID-19 is important to diagnose worsening coagulopathy. The first step in 
management of DIC is to identify and treat the underlying condition(s). Bacterial superinfections 
should be treated aggressively. 
In addition to preventing VTE, LMWH prophylaxis may decrease thrombin generation 
and modify the course of DIC. Preliminary results, albeit with small number of events and 
limited adjustment, may suggest a favorable response from LMWH prophylaxis (82,118). Long-
acting antiplatelet agents should be generally discontinued in most patients with DIC, unless 
required (e.g. recent ACS or stent implantation). For patients with moderate or severe COVID-19 
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and an indication for dual antiplatelet therapy (e.g. PCI within the past 3 months or recent MI) 
and with suspected or confirmed DIC without overt bleeding, in the absence of evidence 
decisions for antiplatelet therapy need to be individualized. In general, it is reasonable to 
continue dual antiplatelet therapy if platelet count ≥50,000, reduce to single antiplatelet therapy 
if 25,000≤platelet count<50,000, and discontinue if platelets <25,000. However, these guidelines 
may be revised upward or downward depending on the individualized relative risk of stent-
related thrombotic complications vs. bleeding. Recovery from DIC is dependent on endogenous 
fibrinolysis breaking down the disseminated thrombi.  
Management of bleeding:  
Clinically-overt bleeding is uncommon in the setting of COVID-19. However, when 
bleeding occurs in COVID-19-associated DIC, blood products support should be considered as 
per septic coagulopathy (119). In summary, the mainstay of blood products transfusion are as 
follows: platelet concentrate to maintain platelet count >50 × 109/L in DIC patients with active 
bleeding or >20 × 109/L in those with a high risk of bleeding or requiring invasive procedures., 
fresh frozen plasma (FFP) (15-25 mL/kg) in patients with active bleeding with either prolonged 
PT and/or aPTT ratios (>1.5 times normal) or decreased fibrinogen (<1.5 g/L), fibrinogen 
concentrate or cryoprecipitate to patients with persisting severe hypofibrinogenemia (<1.5 g/L), 
and prothrombin complex concentrate (PCC) if FFP transfusion is not possible. With the existing 
data, tranexamic acid should not be used routinely in COVID-19-associated DIC. 
Management of Patients with Thromboembolic Disease without COVID-19 
The main goal of management for patients with known or new-onset thrombotic disease 
but without COVID-19 is to provide sufficient antithrombotic protection, while minimizing 
physical contact between patients and healthcare workers and health systems. Outpatient 
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management or early discharge for acute VTE should be instituted when possible (120-122), and 
early discharge after medication stabilization for low-risk ACS or PCI for high-risk ACS should 
be considered (100-102). Telemedicine should be the preferred method of follow-up, and in-
person visits should be reserved only for scenarios that cannot be addressed by telemedicine, or 
that may potentially warrant hospitalization. 
In general, pharmacotherapy in patients with known thrombotic disease and without 
COVID-19, should be followed similar to the period prior to the pandemic. Although a recent 
document from the CDC indicated an increased risk of severe COVID-19 in patients receiving 
“blood thinners” (123), there is no evidence that antiplatelet agents or anticoagulants, increase 
the risk of contracting COVID-19, or of developing severe COVID-19. Sufficient education 
should be provided to patients for self-monitoring of symptoms, and to avoid unnecessary 
emergency department visits for nuisance bleeding. 
 For patients receiving VKAs, frequent INR monitoring may pose logistical challenges 
due to lockdowns and may unnecessarily increase the risk of being exposed to SARS-CoV-2. 
Therefore, thoughtful considerations should be given to potential alternatives, including using 
extended INR testing intervals if prior INRs have been stable (124). Other alternatives include 
home-based INR checks, if this can be set up promptly, drive-through INR testing, or switching 
to a DOAC or LMWHs when clinically appropriate (Figure 3). A summary of key 
recommendations is presented in Table 6. 
Impact of COVID-19 on Healthcare Workers and Health Systems 
Considerations for healthcare workers.  
The CDC recommends contact and droplet personal PPE for healthcare workers in their 
routine care of patients with COVID-19. If an aerosol-generating procedure is being performed 
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(e.g. intubation, extubation, cardiopulmonary resuscitation), additional airborne PPE with an 
N95 respirator is recommended. Use of telemedicine in place of in-person office visits is a 
strategy to minimize physical exposure. Further details have been discussed elsewhere (5,104).  
The following considerations specific to the care of patients with thrombotic disease may 
be useful. Over-the phone and telemedicine approaches should be considered for all non-urgent 
appointments. For necessary in-person visits, visitor restrictions and staggering of appointments 
are important considerations (125). For patients with COVID-19 who require urgent procedures, 
such as interventions for ACS, high-risk PE, or critical limb ischemia, the fewest number of staff 
necessary should be involved. For patients without known infection, healthcare workers should 
screen patients for COVID-19 exposures or infectivity, consider appropriate PPE during the 
procedure, and apply disinfection techniques post-procedure, as outlined previously (126). In 
patients who require, emergent cardiac catheterization with unknown COVID-19 status, airborne 
PPE with an N95 respirator and/or Powered Air Purifying Respirator is recommended (127,128). 
Considerations for health systems.  
Active involvement of health systems with respect to the care of patients with thrombotic 
disease are critical to achieving good outcomes for both COVID-19-infected and uninfected 
patients. If feasible, resources should be allocated to enable at-home or drive-through INR 
checks. Further, system-based considerations should be made to monitor and make necessary 
adjustments to algorithms for management of suspected STEMI or severe PE requiring PERT 
teams. If procedures are deemed necessary for COVID-19 infected patients, specific protocols 
should be put into place regarding PPE use and room disinfection.  
Role of Professional Societies 
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Professional societies, along with other partners, have an important role in knowledge 
generation and dissemination for various aspects of COVID-19 (5,84,104), as well as leading by 
example. Illustrative examples include the responsible and wise decisions by the ACC to cancel 
the 2020 Annual Scientific Sessions, the SCAI to cancel the 2020 Annual Scientific Sessions, 
and the ISTH to cancel the XXVIII Congress of the ISTH to promote social distancing and to 
avoid further spread of the disease. Enabling meetings to continue virtually, as with the recent 
ACC scientific sessions (in this case at no charge) further promotes knowledge dissemination 
and sense of community, allowing a semblance or normality in challenging times. Many 
professional societies, including the ACC, the American Heart Association (AHA), American 
Society of Hematology, ESC, the ISTH, and others, are compiling COVID-related resources in 
dedicated websites. Professional societies can further foster collaborative knowledge generation 
by supporting multicenter multinational original research studies to address the pressing clinical 
or laboratory questions (Figure 4).  
Public Health Considerations Related to Care for Thrombotic Disease 
The WHO and government agencies have recognized the critical importance of public 
health interventions at the societal level (including social distancing and self-isolation) to 
decrease transmission rates and alleviate the burden on health systems (129). In the most affected 
areas, governments have enacted mandatory home quarantine for all non-essential personnel 
(130-132). There are several important issues to consider as these interventions relate to 
thrombotic disease. 
First, given the recommendations to stay at home, with decreased daily activity and 
sedentary lifestyles, patients may be at increased risk for VTE (133-137). Clinicians should be 
aware of this (especially in older adults and higher-risk patients) and provide education on the 
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importance of home activities to mitigate this risk (138). Second, as daily routines are disrupted, 
dietary changes (especially in daily intake of green vegetables, which are the major source of 
vitamin K in the Western diet) may affect patients who receive VKAs. As quarantine measures 
become more severe, changes in diet and vitamin K intake may impact INR values. Providers 
and patients should be aware of these risks, and patients should be advised to maintain stable diet 
to the best of their ability. Third, the COVID-19 pandemic has produced damaging economic 
effects (139), with United Nations estimating that COVID-19 is likely to cost the world economy 
more than $2 trillion in 2020. These losses may adversely affect patients’ treatment for 
thrombotic diseases. Socioeconomic disadvantage has been linked to higher rates of VTE and 
adverse outcomes (140,141). As the economic effects of COVID-19 continue to evolve, these 
communities may come under new and significant stress.  
Future Directions and Conclusions 
More data and higher-quality data are required to learn how COVID-19 and thrombotic 
disease interact. Such data, ideally derived from prospective, multicenter, multinational studies, 
could help to elucidate the similarities and distinctions in disease presentation and outcomes of 
patients with COVID-19 and preexisting and incident thromboembolic disease, and help to 
identify management strategies to optimize outcomes in these patients. Currently, one large 
international registry of patients with venous thromboembolism (the Registro Informatizado 
Enfermedad TromboEmbólica [RIETE]) (142) is incorporating data elements for COVID-19, 
and a dedicated adjudicated prospective registry to study COVID-19 and other cardiovascular 
outcomes is being initiated (CORONA-VTE, BWH Thrombosis Research Group; PI: G. Piazza). 
A multicenter multinational ACS registry is has begun and a new AHA registry for 
cardiovascular care and outcomes of these patients. Special attention should also be given to 
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patients with pre-existing thromboembolic disease who have limited access to care in the face of 
the COVID-19 pandemic, which has hindered transportation and limited the resources of the 
healthcare system. 
Funding agencies, professional societies, and organizations with active patient 
participation will all play an important role when it comes to future research in this area. Funding 
agencies, including the National Institutes of Health (which has already responded swiftly) (143) 
should continue to pay specific attention to this pandemic. Coordination and cooperation are 
necessary to quickly address research priorities including those related to thrombotic disease 
(Table 5). Organizations such as the Patient-Centered Outcomes Research Institute (PCORI) and 
the North American Thrombosis Forum (NATF) can ensure the voices and concerns of patients 
are at the forefront of research questions. Professional societies, including the AHA, ESC, ISTH, 
IUA, and others should promote knowledge generation and dissemination and advocacy in this 
challenging climate. 
The current manuscript has provided an interim summary and guidance for 
considerations related to thrombotic disease and antithrombotic therapy during the COVID-19 
pandemic. Such guidance should supplement, rather than supplant, clinical decision-making. 
Nuances of conversations between patients and practitioners should be considered for 
appropriate patient-centered decisions.   
In conclusion, thrombotic disease may be precedent factors or incident complications in 
patients with COVID-19. Important considerations for the preventive and therapeutic use of 
antithrombotic agents should be kept in mind to mitigate the thrombotic and hemorrhagic events 
in these high-risk patients. Funding agencies, professional societies, patients, clinicians, and 
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investigators should work collaboratively to effectively and efficiently address numerous critical 
areas of knowledge gap. 
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Bullet Points 
• Coronavirus disease 2019 (COVID-19) may predispose patients to arterial and venous 
thrombosis. 
• Initial series suggest the common occurrence of venous thromboembolic disease in 
patients with severe COVID-19. The optimal preventive strategy warrants further investigation. 
• Drug-drug interactions between antiplatelet agents and anticoagulants with 
investigational COVID-19 therapies should be considered. 
• The available technology should be used optimally to care for patients without COVID-
19 who have thrombotic disease during the pandemic. 
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Figure Legends 
Figure 1. Variability in resources and testing strategies, and in contracting COVID-19 after 
exposure to SARS-CoV-2. Such variability explains the dissimilar population rates of the 
infection, and the distinct case fatality rates, across various regions and countries. Inflammatory 
response, increased age, and bed-ridden status –which are more frequently observed in severe 
COVID-19– may contribute to thrombosis and adverse outcomes. Coronavirus Disease 2019 
(COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), VTE indicates 
venous thromboembolism. 
Figure 2. Risk stratification of acute coronary syndromes and venous thromboembolism 
with COVID-19. Proposed algorithm to risk stratify patients based on severity of ACS, VTE, 
and COVID-19 presentations. *High-risk ACS refers to patients with hemodynamic instability, 
left ventricular dysfunction or focal wall motion abnormality, or worsening or refractory 
symptoms. High-risk VTE refers to patients with pulmonary embolism who are 
hemodynamically unstable, have evidence of right ventricular dysfunction or dilatation, or with 
worsening or refractory symptoms. †High-risk COVID-19 refers to patients with high suspicion 
for or confirmed COVID-19, including individuals with high viral load, symptomatic with 
coughing/sneezing or other respiratory symptoms and at risk for requiring intubation and 
aerosolizing viral particles. ‡Hemodynamic support includes intra-aortic balloon pump, 
percutaneous ventricular assist device, and extracorporeal membrane oxygenation. 
Hemodynamic monitoring refers to Swan-Ganz catheter for invasive hemodynamic assessment. 
For potential drug-drug interactions, please refer to Tables 4 and 5. ACS indicates acute 
coronary syndrome; GDMT, guideline-directed medical therapy; TTE, transthoracic 
echocardiogram; VTE, venous thromboembolism. 
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Figure 3. Considerations for Switching Vitamin-K Antagonists (VKAs) Due to Limitations 
with Access to Care or Healthcare Resources During COVID-19 Pandemic. If switching the 
anticoagulant agent is planned, care should be taken to be sure that the patient is able to afford 
and receive the alternative therapy. Contraindications to DOACs include mechanical heart 
valves, valvular AF, pregnancy or breastfeeding, APLS, and co-administration of medications 
including strong CYP3A and P-glycoprotein inhibitors (-azole medications, HIV protease 
inhibitors [dependent on DOAC, may just require dose reduction], CYP3A4 inducers (anti-
epileptics), St. John’s Wort, rifampin, etc. Patient education about stable dietary habits while 
receiving VKA is also important. If DOACs area not available or approved by insurance, 
LMWHs could be used in select cases. Abbreviations: AF: atrial fibrillation, APLS: anti-
phospholipid syndrome, DOAC: direct oral anticoagulant, INR: international normalized ratio, 
LMWH: low-molecular weight heparin, VKA:  vitamin-K antagonist. 
Figure 4. Considerations for Thrombotic Disease for Patients, Healthcare Providers, and 
Health Systems and Professional Societies During the COVID-19 Pandemic. The approach 
to safe evaluation and management of thrombotic disease in patients with COVID-19 has several 
levels of involvement.  Hospitalized patients with existing VTE should continue on 
anticoagulation with consideration of drug-drug interactions, especially with antiviral 
medications (Table 2). Hospitalized patients with reduced mobility should be started on VTE 
prophylaxis. Patients who are discharged or not hospitalized should continue recommended 
anticoagulation therapy. Telemedicine and drive-through or home INR checks can reduce the 
risk of exposure of both patients and healthcare providers to COVID-19 while assuring proper 
management of anticoagulation. In appropriate cases, consider switching VKAs to DOACs to 
diminish the need for frequent INR checks (see Figure 4). Healthcare workers should continue 
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existing precautions including use of PPE and minimizing individual contact with COVID-19 
patients. If emergent procedures for thrombotic disease (e.g. cardiac catheterization, pulmonary 
thrombectomy) are needed, procedure rooms should be disinfected and the use of negative 
pressure operating rooms should be implemented as available. Expedited funding for 
observational and randomized control trials in management of thrombotic disease is encouraged. 
aPTT: activated partial thromboplastin time, DOAC: direct oral anticoagulant, INR: international 
normalized ratio, PT: prothrombin time, PPE: personal protective equipment, VKA: vitamin-K 
antagonist, VTE: venous thromboembolism. 
Central Illustration. Postulated Mechanisms of Coagulopathy and Pathogenesis of 
Thrombosis in COVID-19. A) Sars-COV-2 infection activates an inflammatory response, 
leading to release of inflammatory mediators. Endothelial and hemostatic activation ensues, with 
decreased levels of TFPI and increased tissue factor. The inflammatory response to severe 
infection is marked by lymphopenia, and thrombocytopenia. Liver injury may lead to decreased 
coagulation and antithrombin formation. B) COVID-19 may be associated with hemostatic 
derangement and elevated troponin. C) Increased thromboembolic state results in venous 
thromboembolism, myocardial infarction, or in case of further hemostatic derangement; 
disseminated intravascular coagulation. COPD: chronic obstructive pulmonary disease; CRP: c-
reactive protein; FDP: fibrin degradation product; HF: heart failure; TFPI: tissue factor pathway 
inhibitor; IL: interleukin; LDH: lactate dehydrogenase; PT: prothrombin time. 
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Table 1. Select Summary of Thrombotic and Thromboembolic Events During Viral Outbreaks 
Proposed Mechanisms Event Type Epidemiological data 
Severe Acute Respiratory Syndrome (SARS) 
• Inflammatory cytokine release 
• Critical illness 
• Therapeutic risk factors.(144) 
 
Venous 
Thromboembolism 
• Retrospective analysis of 46 critically ill patients with SARS showed 11 DVT and 7 PE events.(145) 
• Case series of 8 SARS positive ICU patients. Autopsy identified PE in 4, and DVT in 3 individuals.(144) 
Arterial 
Thrombotic 
Events 
• In a prospective series of 75 patients, 2 patients died of acute myocardial infarction (within 3-week period).(146) 
• Case report of an NSTEMI patient who received PCI but subsequently developed STEMI several hours later, 
concerning for immune-mediated plaque instability.(147) 
Other • In a case series of 206 patients with SARS, 5 developed large artery ischemic stroke with DIC present in 2/5.(148) 
• In a retrospective analysis of 157 patients with SARS, isolated, subclinical elevations in aPTT were noted in 96 
patients and DIC developed in 4 patients.(149) 
Middle East Respiratory Syndrome (MERS-CoV) 
• Nonspecific mechanism; potentially  
similar to SARS. Models suggest elevated 
inflammatory cytokine levels.(150) 
• Transgenic murine models show evidence 
of microvascular thrombosis.(151) 
Other • In a series of 161 cases of MERS (confirmed and probable), at least 2 were reported to have a consumptive 
coagulopathy.(152) 
Influenza 
• Possible de novo pulmonary emboli in 
certain cases.(153) 
• Acute inflammation and decreased 
mobility in hospitalized patients.(154) 
• Possible thrombosis due to rupture of pre-
existing high risk plaques.(99) 
• Platelet aggregation over inflamed 
atherosclerotic plaques noted in animal 
models.(155) 
Venous 
Thromboembolism 
 
• Retrospective study of 119 patients showed 4 VTE events in patients receiving prophylactic anticoagulation.(154) 
• Case series describes 7 PEs in patients with influenza pneumonia. In 6/7 there was no evidence of DVT.(153) 
• A multicenter, observational, case-control study (n=1454) suggests lower VTE rates are associated with influenza 
vaccination (odds ratio: 0.74; 95% CI: 0.57-0.97).(156) 
• This is a representative but not comprehensive list of associated studies. 
Arterial 
Thrombotic 
Events 
• A self-controlled study of 364 patients hospitalized with acute myocardial infarction found an increased incidence 
ratio (IR=6.05, 95% confidence interval: 3.86 to 9.50) for myocardial infarction during periods after influenza 
compared with controls.(157) Similar evidence exists in prior studies.(158,159) 
• A retrospective cohort study of 119 patients reports 3 arterial thrombotic events, two of which had STEMI (154). 
• This is a representative but not comprehensive list of associated studies. 
Other • DIC has been described with influenza infection in a number of case reports and small case series (160-162). 
COVID-19 
• Mechanistic understanding continues to 
evolve.  
• Factors may include inflammatory 
cytokine release and critical 
illness/therapeutic risk factors.  
• SARS-CoV-2 binds cells expressing 
angiotensin converting enzyme 2 (163) and 
this may mediate further mechanisms of 
injury.(164) 
Venous 
Thromboembolism 
• In a preprint retrospective study, 10/25 patients who underwent computed tomography pulmonary angiography had 
acute PE (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548771)  
• Two-case series of acute pulmonary embolism were described in patients hospitalized with COVID-19.(83) 
• In a study from 3 hospitals from the Netherlands, 31% of 184 critically-ill patients with COVID-19 had VTE. 
Arterial 
Thrombotic 
Events 
• Evidence regarding ACS with concurrent COVID-19 infection is limited to anecdotal reports. A pre-print single-
center retrospective study reported 11 cases of acute ischemic stroke among 221 patients with COVID-19 
(https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550025) 
• Data are continuing to emerge regarding the risk of thrombotic events associated with COVID-19 infection, and an 
international registry for ACS is planned. Please see text for more detail. 
Other Retrospective analysis of 183 patients found non-survivors had significantly higher D-dimer and PT values, compared with 
survivors. Further, 15/21 (71.4%) of non-survivors met criteria for DIC, versus 1/162 (0.6%) of survivors.(7) 
Systematic review of literature published prior to February 24, 2020 suggests elevations in PT and D-dimer levels were 
associated with poor prognosis in patients with COVID-19.(165) 
ACS = acute coronary syndrome; aPTT = activated partial thromboplastin time; COVID-19 = coronavirus disease of 2019; DIC = disseminated intravascular coagulation; DVT = deep vein 
thrombosis; ICU= intensive care unit; MERS = Middle East Respiratory Syndrome;  NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; PE = pulmonary 
embolism; PT = prothrombin time; SARS = severe acute respiratory syndrome; STEMI = ST-elevation myocardial infarction; VTE = venous thromboembolism. 
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Table 2. Association Between Coagulation Abnormalities or Markers of Thrombosis and Hemostasis and Clinical Outcomes in Patients with COVID-19 
 Han 2020 
(N=94)(24) 
Huang 2020 
(N=41)(1) 
Yang 2020 
(N=52)(26) 
Zhou et al 
(N=191)(20) 
Gao 2020 
(N=43)(27) 
Wang 2020 
(N=138)(16) 
Wu 2020 
(N=201)(19) 
Tang 2020 
(N=183)(7) 
Lippi 2020 
(N=1779)(2
2) 
Lippi 2020 
(N=553)(23) 
Lippi 2020 
(N=341)(36) 
Platelet count 
Setting of Comparison  ICU vs. non-
ICU 
Dead vs. 
alive 
Dead vs. 
alive 
 ICU vs. non-
ICU 
Dead vs. 
alive 
 Dead vs. 
alive 
  
Platelet Count  196 (165-
263) vs. 149 
(131-263) 
191 (74) vs. 
164 (63) 
166 (107-
229) vs. 220 
(168-271) 
 142 (110-
202) vs. 165 
(125-188) 
162 (111-
231) vs. 204 
(137-263) 
 -48 (-57 - -
39)*^ 
  
D-dimer (mg/L) 
Setting of Comparison Severe vs. 
non-severe 
ICU vs. non-
ICU 
 Dead vs. 
alive 
Severe vs. 
non-severe 
ICU vs. non-
ICU 
Dead vs. 
alive 
Dead vs. 
alive 
 Severe vs. 
non-severe 
 
D-dimer (mg/L) 19.1 vs. 2.1 2.4 (0.6-
14.4) vs. 0.5 
(0.3-0.8) 
 5.2 (1.5-
21.1) vs. 0.6 
(0.3-1.0) 
0.5 (0.3-0.9) 
vs. 0.2 (0.2-
0.3) 
0.4 (0.2-
13.2) vs. 0.2 
(0.1-0.3) 
4.0 (1.0-
11.0) vs. 0.5 
(0.3-1.2) 
2.1 (0.8-5.3) 
vs. 0.6 (0.4-
1.3) 
 3.0 (2.5-
3.5)* 
 
Prothrombin time (s) 
Setting of Comparison Severe vs. 
non-severe 
ICU vs. non-
ICU 
Dead vs. 
alive 
Dead vs. 
alive 
Severe vs. 
non-severe 
ICU vs. non-
ICU 
Dead vs. 
alive 
Dead vs. 
alive 
   
Prothrombin time (s) 12.7 vs. 12.2 12.2 (11.2-
13.4) vs. 
10.7 (9.8-
12.1) 
12.9 (2.9) 
vs. 10.9 
(2.7) 
12.1 (11.2-
13.7) vs. 
11.4 (10.4-
12.6) 
11.3 (1.4) 
vs. 12.0 
(1.2) 
13.2 (12.3-
14.5) vs. 
12.9 (12.3-
13.4) 
11.6 (11.1-
12.5) vs. 
11.8 (11.0-
12.5) 
15.5 (14.4-
16.3) vs. 
13.6 (13.0-
14.0) 
   
Troponin (hs-TnI) 
Setting of Comparison  ICU vs. non-
ICU 
 Dead vs. 
alive 
 ICU vs. non-
ICU 
    Severe vs. 
non-severe 
Troponin (hs-TnI)  3.3(3.0-
163.0) vs. 
3.5 (0.7-5.4) 
 22.2 (5.6-
83.1) vs. 3.0 
(1.1-5.5) 
 11.0 (5.6-
26.4) vs. 5.1 
(2.1-9.8) 
    25.6 (6.8-
44.5)* 
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Table 3. Potential Drug Interactions Between Antiplatelet Agents* and Investigational Therapies for COVID-19 
 
 P2Y12 Platelet Receptor Inhibitors Phosphodiesterase III 
Inhibitor 
Investigational COVID-19 
Therapies 
Mechanism of Action of COVID-19 Therapy Clopidogrel 1,2 Prasugrel 2 Ticagrelor 3,4 Cilostazol 
Lopinavir/ 
Ritonavir 
Lopinavir is a protease inhibitor; Ritonavir inhibits CYP3A4 metabolism 
increasing lopinavir levels 
CYP 3A4 Inhibition (minor pathway): 
Reduction in clopidogrel active metabolite. 
Do not co-administer or if available utilize 
P2Y12 platelet function assays for 
monitoring.† With limited clinical data, 
prasugrel may be considered as alternative, 
if no contraindications 
CYP3A4 Inhibition: Decreased 
active metabolite but maintained 
platelet inhibition. Can administer 
with caution. 
CYP3A4 Inhibition: 
Increased effects of ticagrelor. 
Do not co-administer or if 
available utilize P2Y12 
monitoring or consider dose-
reduced ticagrelor*  
CYP3A4 Inhibition: 
Recommend decreasing dose 
to maximum of 50 mg BID. 
Remdesivir Nucleotide-analog inhibitor of RNA-dependent RNA polymerases Reported inducer of CYP3A4 (minor 
pathway): No dose adjustment 
recommended. 
Reported inducer of CYP3A4 
(major pathway): No dose 
adjustment recommended. 
Reported inducer of 
CYP3A4 (major pathway): 
No dose adjustment 
recommended. 
Reported inducer of 
CYP3A4 (major pathway): 
No dose adjustment 
recommended. 
Tocilizumab Inhibits IL-6 receptor: may potentially mitigate cytokine release syndrome 
symptoms in severely ill patients 
Reported increase in expression of 2C19 
(major pathway) and 1A2, 2B6, and 3A4 
(minor pathways: No dose adjustment 
recommended. 
Reported increase in expression of 
3A4 (major pathway) and 2C9 and 
2C19 (minor pathway): No dose 
adjustment recommended. 
Reported increase in 
expression of 3A4 (major 
pathway):  No dose 
adjustment recommended. 
Reported increase in 
expression of 3A4 (major 
pathway): No dose 
adjustment recommended.  
Sarilumab Binds specifically to both soluble and membrane-bound IL-6Rs (sIL-6Rα and 
mIL-6Rα) and has been shown to inhibit IL-6-mediated signaling: may 
potentially mitigate cytokine release syndrome symptoms in severely ill 
patients 
Reported increase in expression of 3A4 
(minor pathways: No dose adjustment 
recommended. 
Reported increase in expression of 
3A4 (major pathway): No dose 
adjustment recommended. 
Reported increase in 
expression of 
CYP3A4(major pathway): 
No dose adjustment 
recommended. 
Reported increase in 
expression of 3A4 (major 
pathway): No dose 
adjustment recommended. 
Other drugs being studied to treat COVID-19 include azithromycin, bevacizumab, chloroquine/hydroxychloroquine, eculizumab, fingolimod, interferon, losartan, methylprednisolone, pirfenidone, and ribavirin. Drug-drug interactions between these medications and 
antiplatelet agents have yet to be identified. *Cangrelor, aspirin, dipyridamole, and glycoprotein IIb/IIIa inhibitors (eptifibatide, tirofiban, abciximab) are not known to interact with investigational therapies for COVID-19.  
†Monitoring of P2Y12 levels can be assessed through the VerifyNow assay, or others. Evaluation of effect of protease inhibitors on P2Y12 inhibitors has not been extensively studied. Dose reduction recommendations for P2Y12 inhibitors or P2Y12 platelet function 
assay monitoring is not commonly practiced. 
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Table 4. Potential Drug Interactions Between Anticoagulants* and Investigational Therapies for COVID-19 
Oral Anticoagulants 
Investigational COVID-19 
Therapies Vitamin K antagonists Dabigatran Apixaban Betrixaban Edoxaban Rivaroxaban 
Lopinavir/Ritonavir 
CYP2C9 induction: 
May decrease plasma concentration. Adjust 
dose based on INR 
 
P-gp inhibition: 
May increase plasma 
concentration. No dose 
adjustment recommended 
CYP3A4 and P-gp inhibition: 
Administer at 50% of dose 
(do not administer if initial dose is 2.5 
mg twice daily)† 
P-gp and ABCB1 inhibition: 
Decrease dose to 80 mg once 
followed by 40 mg once daily 
 
P-gp inhibition: 
Do not co-administer 
 
CYP3A4 and P-gp inhibition: 
Do not co-administer 
Tocilizumab - - 
Reported increase in expression of 
3A4 (major pathway):  No dose 
adjustment recommended 
- - 
Reported increase in expression of 3A4 
(major pathway):  No dose adjustment 
recommended 
Interferon‡ 
 
Unknown mechanism: 
Decreased dose may be needed - - - - - 
Ribavirin 
Mechanism not well known:  
Possibly decreased absorption of warfarin in 
the presence of ribavirin.(166) 
Increased dose may be needed 
- - - - - 
Methylprednisolone Unknown mechanism: Decreased dose may be needed - - - - - 
Sarilumab§ 
 
 
 
Reported increase in expression of 
CYP3A4 (major pathway): No dose 
adjustment recommended 
  
Reported increase in expression of 
CYP3A4 (major pathway):  No dose 
adjustment recommended 
Azithromycin Unknown mechanism: Decreased dose may be needed 
P-gp inhibition: 
May increase plasma 
concentration. No dose 
adjustment recommended 
 
P-gp inhibition:  
Decrease dose to 80 mg once 
followed by 40 mg daily 
P-gp inhibition: 
VTE: Limit dose to 30 mg 
daily.  
Non-valvular AF: No dose 
recommendation  
 
Hydroxychloroquine and 
Chloroquine - - - - - - 
Other drugs being studied to treat COVID-19 include bevacizumab, chloroquine/hydroxychloroquine, eculizumab, fingolimod, losartan, and pirfenidone. Drug-drug interactions between these medications and oral anticoagulants have yet to be identified. Bevacizumab 
has been reported to cause deep vein thrombosis (9%), arterial thrombosis (5%) and pulmonary embolism (1%). It is also reported to cause thrombocytopenia (58%).*Parenteral anticoagulants (including unfractionated or low-molecular weight heparins, bivalirudin, 
argatroban, and fondaparinux) are non CYP metabolized and don’t interact with any of the investigational agents #Reported with interferon alpha. †These recommendations are based on the U.S. package insert. The Canadian package insert considers the combination of 
these agents to be contraindicated. ‡Interferon has been reported to cause pulmonary embolism (<5%), thrombosis (<5%), decreased platelet count (1-15% with Alfa-2b formulation), and ischemic stroke (<5%). §Sarilumab has been reported to cause decreased platelet 
count, with decreases to less than 100,000 mm3 in 1% an 0.7% of patients on 200 mg and 150 mg doses, respectively. CYP: Cytochrome P system. | 
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Table 5. Areas Requiring Further Investigation 
 Patients with Mild COVID-19 (outpatient) Comment 
 To determine the optimal method for risk assessment for outpatients with mild COVID-19 who are 
at risk of VTE 
The options include the Caprini model, the IMPROVE model, and the Padua model, 
and others for assessment of the risk of VTE. These should be weighed against the 
risk of bleeding. 
 To determine the incidence acute coronary syndromes in population-based studies  
 Patients with Moderate or severe COVID-19 without DIC (hospitalized)  
 To determine the incidence and predictors of VTE among patients with COVID-19 who present with 
respiratory insufficiency and/or hemodynamic instability. These include lower extremity DVTs, 
central-line associated DVT in upper or lower extremities, and also PE. 
Prospective multicenter cohort (observational) data needed, these protocols should 
not interfere and could run in parallel with interventional trials which are planned or 
already underway. 
 To develop an appropriate algorithm for the diagnosis of incident VTE in patients with COVID-19.  D-dimer is elevated in many inpatients with COVID-19, although negative value 
may still be helpful. In some cases of COVID-19 with worsening hypoxemia, CTPA 
may be considered instead of non-contrast CT (which only assesses the pulmonary 
parenchyma. Unresolved issues include diagnostic tests for critically-ill patients, 
including those in prone position, with limited options for CTPA or ultrasonography. 
 To determine the optimal total duration of prophylactic anticoagulation Ultrasound screening in select patients may need to be studied. 
 To determine the optimal dose of prophylactic anticoagulation in specific populations (e.g. those 
with obesity or advanced kidney disease) 
Weight-adjusted prophylactic dosing for patients with obesity, or dosing based on 
creatinine clearance in patients with kidney disease require further investigation. 
 To determine if LMWH constitutes the preferred method of pharmacological prophylaxis  
 To determine the optimal method for risk stratification and VTE prophylaxis after hospital discharge The options include the Caprini model, the IMPROVE model, and the Padua model, 
and others for assessment of the risk of VTE. These should be weighed against the 
risk of bleeding. 
 To determine if routine use of higher doses of anticoagulants (i.e. higher than prophylactic doses as 
described in the international guidelines), confer net benefit 
An important question would be whether monitoring anti-Xa activity would be 
preferable over aPTT. 
 To determine the incidence and predictors of type I acute myocardial infarction in patients with 
COVID-19, and to compare their process measures and outcomes with non-infected patients. 
 
 To determine the potential role of agents including danaparoid, fondaparinux, and sulodexide in 
select patients with moderate/severe COVID-19. 
 
 
 Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)  
 To determine if routine use of pharmacological VTE prophylaxis or low or standard dose 
anticoagulation with UFH or LMWH  is warranted (if no overt bleeding) 
A relevant question is whether prophylactic, or other, dose anticoagulation should be 
given to patients with DIC who do not have bleeding, even without immobility 
 To determine if additional clinical characteristics and variables in the setting of DIC (e.g. 
lymphopenia) should be considered to help risk-stratify and assess prognosis 
 
 To determine utility of other interventions including antithrombin concentrates.  
 Patients without COVID-19 but with co-morbidities, and homebound during the pandemic  
 To determine the optimal method of screening and risk stratification for consideration of VTE 
prophylaxis 
The options include the Caprini model, the IMPROVE model, and the Padua model, 
and others for assessment of the risk of VTE. These should be weighed against the 
risk of bleeding. 
 To conduct population-level studies to determine the trends in incidence and outcomes of thrombotic 
disease in the period of reduced office visits 
Although telemedicine is reasonable to control the COVID-19 pandemic, potential 
adverse consequences on non-communicable disease, including thrombotic disease 
deserve investigation.  
aPTT: activated partial thromboplastin time, COVID-19: Coronavirus disease 2019; CTPA: computed tomography pulmonary angiography; LMWH: low-molecular weight heparin; PE: pulmonary 
embolism; VTE: Venous thromboembolism 
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Table 6. Summary of Consensus Recommendation on Antithrombotic Therapy During the COVID-19 Pandemic  
 Patients with Mild COVID-19 (outpatient) 
 For outpatients with mild COVID-19, increased mobility should be encouraged. Although indiscriminate use of pharmacological VTE prophylaxis should not be pursued, assessment for the risk of VTE 
and  of bleeding is reasonable. Pharmacologic prophylaxis could be considered after risk assessment on an individual case basis for patients who have elevated risk VTE, without high bleeding risk.* 
 There is no known risk of developing severe COVD-19 due to taking antithrombotic agents (i.e. antiplatelet agents or anticoagulants). If patients have been taking antithrombotic agents for prior known 
thrombotic disease, they should continue their antithrombotic agents as recommended. 
 For outpatients on vitamin K antagonists who do not have recent stable INRs, and are unable to undergo home or drive-through INR testing, it is reasonable to transition the treatment DOACs if there 
are no contraindications and no problems with drug availability and affordability. If DOACs are not approved or available, low-molecular weight heparin can be considered as alternative.* 
 Patients with Moderate or Severe COVID-19 without DIC (hospitalized) 
 Hospitalized patients with COVID-19 should undergo risk stratification for VTE prophylaxis. 
 For hospitalized patients with COVID-19 and not in DIC, prophylactic doses of anticoagulation can be administered to prevent VTE.*¥† If pharmacological prophylaxis is contraindicated, it is 
reasonable to consider intermittent pneumatic compression. 
 For hospitalized patients with COVID-19 and not in DIC, there is insufficient data to consider routine therapeutic or intermediate-dose parenteral anticoagulation with UFH or LMWH.*‡ 
 Routine screening for VTE (e.g. bilateral lower extremity ultrasound) for hospitalized patients with COVID-19 with elevated D-Dimer (>1,500 ng/mL) cannot be recommended at this point& 
 
 
Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized) 
 For patients with moderate or severe COVID-19 and in DIC but without overt bleeding, prophylactic anticoagulation should be administered.*¥§ 
 For hospitalized patients with COVID-19 with suspected or confirmed DIC, but no overt bleeding, there is insufficient data to consider routine therapeutic or intermediate-dose parenteral 
anticoagulation with UFH or LMWH.*β 
 For patients with moderate or severe COVID-19 on chronic therapeutic anticoagulation, who develop suspected or confirmed DIC without overt bleeding, it is reasonable to consider the indication for 
anticoagulation and weigh with risk of bleeding when making clinical decisions regarding dose adjustments or discontinuation. The majority of authors of this manuscript recommended reducing the 
intensity of anticoagulation in this clinical circumstance, unless the risk of thrombosis considered to be exceedingly high. || 
 For patients with moderate or severe COVID-19 and an indication for dual antiplatelet therapy (e.g. percutaneous coronary intervention within the past 3 months or recent myocardial infarction) and 
with suspected or confirmed DIC without overt bleeding, in the absence of evidence, decisions for antiplatelet therapy need to be individualized. In general, it is reasonable to continue dual antiplatelet 
therapy if platelet count >50,000, reduce to single antiplatelet therapy if 25,000<platelet count<50,000; and discontinue if platelets <25,000. However, these guidelines may be revised upward or 
downward depending on the individualized relative risk of thrombotic complications vs. bleeding. 
 For patients who were admitted and are now being discharged for COVID-19, routine screening for VTE risk is reasonable for consideration of pharmacological prophylaxis for up to 45 days post-
discharge. Pharmacological prophylaxis should be considered if there is elevated risk for thrombotic events, without high bleeding risk. *# 
Ambulation and physical activity should be encouraged. 
 Patients with COVID-19 presenting with ACS 
 For presentations concerning for STEMI and COVID-19, clinicians should weigh the risks and severity of STEMI presentation with that of potential COVID-19 severity in the patient, as well as risk of 
COVID-19 to the individual clinicians and to the healthcare system at large. Decisions for primary percutaneous coronary intervention or fibrinolytic therapy should be informed by this assessment.* 
 Patients without COVID-19 who have previously-known thrombotic disease  
 There is no known risk of developing severe COVD-19 due to taking antithrombotic agents. Patients should continue their antithrombotic agents as recommended. 
 To minimize risks associated with healthcare worker and patient in-person interactions, follow-up with e-visits and telemedicine is preferable in most cases. 
 Patients without COVID-19 who develop new thrombotic disease 
 To minimize risks associated with healthcare worker and patient in-person interactions, in-home treatment or early discharge should be prioritized. 
 To minimize risks associated with healthcare worker and patient in-person interactions, follow-up with e-visits and telemedicine is preferable in most cases. 
 Patients without COVID-19 but with co-morbid conditions (e.g. prior VTE, active cancer, major cardiopulmonary disease), who are homebound during the pandemic 
 Recommendations include increased mobility, and risk assessment for the risk of VTE and risk of bleeding is reasonable. Administration of pharmacologic prophylaxis could be considered after risk 
assessment on an individual case basis for patients who have elevated risk for thrombotic events, without high bleeding risk. 
*Indicates recommendations as reached by consensus of at least 66% of authors determined via Delphi method. ¥Although high-quality data are lacking, some panel members (55%) considered it reasonable to use 
intermittent pneumatic compression in patients with severe COVID-19, in addition to pharmacological prophylaxis. Specific areas of concern included limited data on use in the prone position as well as potential 
high incidence of preexisting asymptomatic DVT. †If VTE prophylaxis is considered, enoxaparin 40mg daily or similar LMWH regimen (e.g. dalteparin 5000U daily) can be administered. Subcutaneous heparin 
(5000U twice to three times per day) can be considered for patients with renal dysfunction (i.e. creatinine clearance <30 mL/min). ‡While the majority of the writing group did make this recommendation, 31.6% of 
the group were in favor of intermediate-dose anticoagulation [e.g. enoxaparin 1mg/kg/day, or enoxaparin 40mg BID, or UFH with target aPTT of 50-70] and 5.2% considered therapeutic anticoagulation. &The 
majority of the investigators recommended against routine VTE screening (68%); however, the remaining members of the group (32%) recommended to consider such testing. §The majority of the investigators 
recommended prophylactic anticoagulation (54%). A minority of investigators (29.7%) voted for intermediate-dose parenteral anticoagulation in this setting, and 16.2% considered therapeutic anticoagulation. ||While 
the majority of investigators voted to reduce the intensity of anticoagulation if the indication were not acute (62%), this survey question did not meet prespecified cut-off of 66%. #The majority of the writing group 
recommended prophylaxis with DOACs (51%) and minority (24%) recommended LMWH, if available and appropriate. ACS: acute coronary syndrome; DOAC: direct oral anticoagulant, LMWH, low-molecular 
weight heparin; STEMI, ST-segment elevation myocardial infarction; UFH, unfractionated heparin; VTE, venous thromboembolism. 





